Ridgeback Biotherapeutics
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia
The treatment is to protect children under two years of age from respiratory syncytial virus
Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment
Quotient’s somatic genomics platform technology will be used to develop the treatment
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
Merck announces agreement with US government to reduce prices of prescription medication
The pharma company will invest more than $70bn in the US to boost production and innovation
Merck agrees deal with Cidara Therapeutics worth almost $9.2bn
Cidara’s long-acting viral flu drug showed significant protection in phase 2 results
Merck ends development agreement with Dr Falk Pharma for monoclonal antibody
Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate
Merck and Blackstone agree on funding for cancer protein antibody
The funding will support late-stage clinical development of the investigational antibody-drug conjugate
David Weinreich appointed as Merck’s head of R&D and CMO for healthcare
Weinreich brings clinical development and venture capital experience to the role
AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation
Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment